MARKET

CCCC

CCCC

C4 Therapeutics, Inc.
NASDAQ
7.94
-0.11
-1.34%
Opening 09:59 03/28 EDT
OPEN
8.05
PREV CLOSE
8.05
HIGH
8.10
LOW
7.87
VOLUME
104.00K
TURNOVER
0
52 WEEK HIGH
11.88
52 WEEK LOW
1.060
MARKET CAP
544.85M
P/E (TTM)
-2.9757
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CCCC last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at CCCC last week (0311-0315)?
Weekly Report · 03/18 09:02
Weekly Report: what happened at CCCC last week (0304-0308)?
Weekly Report · 03/11 09:02
C4 Therapeutics Initiates Stock Option Repricing for Retention
TipRanks · 03/08 21:23
C4 Therapeutics To Present New Preclinical Data On Highly Selective Orally Bioavailable BiDAC Degraders At The American Association For Cancer Research Annual Meeting 2024
C4 Therapeutics, Inc. Accepted two preclinical poster presentations at the American Association for Cancer Research Annual Meeting 2024 in San Diego. The company is a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science. C4T's CFT1946 is a BRAF V600X mutant-specific degrader.
Benzinga · 03/05 21:35
U.S. RESEARCH ROUNDUP-Bark, Fleetcor Technologies, Tesla
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Bark, Fleetcor Technologies and Tesla are among the companies. The analysts raised their ratings on Bark and raised their targets for Fleetcor and Tesla. The companies are all listed on the New York Stock Exchange.
Reuters · 03/05 06:57
BUZZ-U.S. STOCKS ON THE MOVE-Avidity, C4 Therapeutics, Avadel Pharma
U.S. Stocks were set for a muted open on Monday. Dow e-minis were down 0.51% in early trading. The S&P 500 and the Nasdaq's record-closing highs in the prior session. The top three NYSE percentage gainers were Avidity, C4 Therapeutics, Avadel Pharma.
Reuters · 03/04 14:29
BUZZ-C4 Therapeutics rises on license agreement with Merck KGaA
Shares of drug developer C4 Therapeutics rise 2.27% to $11.24 premarket. Co says it has entered into a license agreement with Merck KGaA to discover two drugs that target cancer causing proteins. C4 to receive an upfront payment of $16 million.
Reuters · 03/04 12:54
More
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. It leverages its technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to design and optimize small-molecule medicines that harness the body's natural protein recycling system to rapidly degrade disease-causing proteins. Its TORPEDO platform enables the discovery of targeted investigational small molecule medicines called protein degraders. Its advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma (MM), and non-Hodgkin lymphomas (NHLs). Its other product candidate, CFT8634, is an orally bioavailable BiDAC degrader of a protein target called BRD9 for the treatment of synovial sarcoma and SMARCB1-null solid tumors.

Webull offers C4 Therapeutics Inc stock information, including NASDAQ: CCCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCCC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CCCC stock methods without spending real money on the virtual paper trading platform.